

Reference

- Alba LM, Lindor K. (2003). Review Article: Nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 17:977–986.
- Anthony J.G. Hanley, Lynne E. Wagenknecht, DRPH; Andreas Festa, MD; Ralph B. D’Agostino, Jr., PHD; Steven M. Haffner, MD. (2007). The Insulin Resistance Atherosclerosis Study .*Diabetes Care*, Volume 30, Number 7.
- Baig NA, Herrine SK, Rubin R. (2001). Liver disease and diabetes mellitus. *Clin Lab Med* 21:193–207.
- Bantle JP, Wylie-Rosett J, Albright AL, et al. (2006). "Nutrition recommendations and interventions for diabetes—2006: a position statement of the American Diabetes Association". *Diabetes Care* 29 (9): 2140–57.
- Barnard ND, Katcher HI, Jenkins DJ, Cohen J, Turner-McGrievy G. (2009). "Vegetarian and vegan diets in type 2 diabetes management". *Nutrition Reviews* 67 (5): 255–63.
- Bishop ML, Fody EP, Schoeff LE. (2005). *Clinical chemistry principles, procedures, correlation*, 5th ed. Newyork: Lippincott Willliam and Wilkins.
- Chang AM, Halter JB. (2003). "Aging and insulin secretion". *American Journal of Physiology. Endocrinology and Metabolism* 284 (1): E7–12.

- Diabetes Prevention Program Research Group. (2009). "10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study". Lancet 374 (9702): 1677–1686.
- Dubois, HFW and Bankauskaite, V. (2005). ["Type 2 diabetes programmes in Europe"](#).EuroObserver7(2):5–6.
- Elizabeth H. Harris, MD. (2005). Elevated Liver Function Tests in Type 2 Diabetes. Clinical Diabetes, Volume 23, Number 3.
- Erbey JR, Silberman C, Lydick E. (2000).Prevalence of abnormal serum alanine aminotransferasem levels in obese patients and patients with type 2 diabetes. Am J Med 109:588–590.
- Eric S. Allen. (2002). Human Anatomy & Physiology Northeastern University December 7th, 2002.
- Feldman M, et al. (2006).Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 8th ed. Philadelphia, Pa.: Saunders Elsevier; 1575.
- Green RM, et al. (2002). AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 123:1367.

- Grove J, Daly AK, Bassendine MF, Day CP. (1997). Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. *Hepatology*. 26:143–146.
- Handelsman, Yehuda, MD. "A Doctor's Diagnosis. (2009).Prediabetes." *Power of Prevention*, Vol 1, Issue 2.
- Harold E. Lebovitz , MD, Margaret kreider , PHD, Martin I. Freed , MD (MAY 2002) . "Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials". *Diabetes Care* 25:815–821, 2002.
- Harris MI, Flegal KM, Cowie CC, et al. (April 1998). "Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994". *Diabetes Care* 21 (4): 518–24.
- Himsworth. (1936). "Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types". *Lancet* i: 127–30.
- Ji-Sun Lim, Duk-Hee Lee, Joo-Yun Park, Soo-Hee Jin, and David R. Jacobs, Jr. (2007). National Health and Nutrition Examination Survey. *Clinical Chemistry* 53:6 1092–1098.
- Knowler WC, Barrett-Connor E, Fowler SE, et al. (February 2002) .["Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin"](#). *The New England Journal of Medicine* 346 (6): 393–403.

- L M Tierney, S J McPhee, M A Papadakis. (2002). Current medical Diagnosis & Treatment. International edition. New York: Lange Medical Books/McGraw-Hill. pp. 1203–15.
- Lewis GF, Carpentier A, Khosrow A, Giacca A. (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr Rev* 23:201–229.
- Lindström J, Ilanne-Parikka P, Peltonen M, et al. (November 2006). "Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study". *Lancet* 368 (9548): 1673–9.
- Lyssenko V, Jonsson A, Almgren P, et al. (November 2008). "Clinical risk factors, DNA variants, and the development of type 2 diabetes". *The New England Journal of Medicine* 359 (21): 2220–32.
- Melissa Palmer. (2004). " Dr. Melissa Palmer's Guide of Hepatitis and Liver Disease". (Published 2004. Penguin Putnam).
- Mohamadnejad, M. A. Pourshams, R. Malekzadeh, A, Mohamadkhani and A. Rajabiani et al(2003).Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors. *World J. Gastroenterol*, 9:2322-2324.
- Monica Nannipieri, MD ;Clicerio Gonzales, MD ;Simona Baldi, PHD ;Rosalinda Posadas, PHD ;Ken Williams,

MSC ;Steven M. Haffner, MD ;Michael P. Stern, MD ;Ele Ferrannini, MD. (2005). The Mexico City Diabetes Study.Diabetes Care, Volume 28, Number 7.

- Najma Zaheer Baquer , Dhananjay Gupta and Gayadev Raju. (1998) .Regulation of Metabolic Pathway in Liver and Kidney during Experimental Diabetes.Indian Journal of Clinical Biochemistry, 13(2), 63-80.
- Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis. (2003).summary of AASLD single topic conference. Hepatology 37:1202–1219.
- Nyblom H, Berggren U, Balldin J, Olsson R. (2004). ["High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking"](#). Alcohol Alcohol. 39 (4): 336–9.
- Nyblom H, Björnsson E, Simrén M, Aldenborg F, Almer S, Olsson R. (September 2006). ["The AST/ALT ratio as an indicator of cirrhosis in patients with PBC"](#). Liver Int. 26 (7): 840–5.
- O'Brien RM, Granner DK. (1991).Regulation of gene expression by insulin. Biochem J 278:609–619.
- Ohlson LO, Larsson B, Bjorntorp P, Erkksson H, Svardssudd K,Welin L, Tibblin G,Wilhelmsen L. (1988).Risk factors for type 2 diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31:798–305.

- [Orrell JM](#), [Neithercut WD](#), [Henderson J](#), [Spooner RJ](#), [McGuire G](#), [Frier BM](#)(1990). "Raised liver associated enzyme activity and post-prandial bile acid concentrations in sera from treated diabetic outpatients". [Diabetes Research Clinical Practice](#).
- Perry IJ,Wannamethee SG, Shaper AG. (1998) .Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 21:732–737.
- Philippe Andr E, MD; Beverley Balkau, PHD; Sylviane Vol, MSC; Marie Aline Charles, MD; Eveline Eschw Ege, MD. (2007). Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort.Diabetes Care, Volume 30, Number 9.
- Rother KI. (2007). "Diabetes treatment—bridging the divide". The New England Journal of Medicine 356 (15): 1499–501.
- Salmela PI, Sotaniemi EA, Niemi M, Maentausta O. (1984).Liver function tests in diabetic patients. Diabetes Care 7:248–254.
- Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. (2000).Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ab/ab mice. Mol Cell 6:77–86.
- Von Mehring J, Minkowski O. (1890). "Diabetes mellitus nach pankreasexstirpation". Arch Exp Pathol Pharmakol 26: 371–387.

- Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. (2002). High alanine aminotransferases is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes* 51:1889–1895.
- Wannamethee G, Ebrahim S, Shaper AG. (1995). Gamma-glutamyltransferase: determinants and associations with mortality from ischaemic heart disease and all causes. *Am J Epidemiol* 42:699–708.
- Wild S, Roglic G, Green A, Sicree R, King H. (2004). "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030". *Diabetes Care* 27 (5).
- Zilva, Joan F, and Pannall P.R. (1994). *Clinical chemistry in diagnosis and treatment*, 6th ed. England: Hazell Watson and Viney LTD. 218-220.